Glizid-M Tablet is a combination oral antidiabetic medication containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to effective blood glucose regulation. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glizid-M suitable for patients inadequately controlled by diet and exercise alone or monotherapy. The tablet should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of blood glucose levels and renal function is recommended during therapy to optimize dosing and detect potential adverse effects. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Glizid-M is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to its components. This combination therapy offers a convenient and effective option for improving glycemic control, thereby reducing the risk of diabetes-related complications when used as part of a comprehensive treatment plan including diet, exercise, and lifestyle modification.